PainReform sets IPO terms with plans to offer 2.55 million units priced at $8 to $10 each

/ / News

PainReform Ltd. , an Israeli start up that is aiming to develop non-opioid post-surgery pain treatments, set terms for its initial public offering on Monday, with plans to offer 2.55 million units priced at $8 to $10 each. Each unit will consist of one ordinary share and a warrant to purchase a share, the company said in a regulatory filing. The company has applied to list on Nasdaq under the ticker “PRFX.” Maxim Group and Joseph Gunnar & Co. are underwriting the deal. Proceeds will be used to fund clinical trials, and for general corporate purposes. “Our proprietary extended release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates,” the company says in its prospectus.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.